How to publish with us
Clinical Drug Investigation is a hybrid open access journal. Once the article is accepted for publication, authors will have the option to choose how their article is published:
- Traditional publishing model – published articles are made available to institutions and individuals who subscribe to Clinical Drug Investigation or who pay to read specific articles.
- Open Access – when an article is accepted for publication, the author/s or funder/s pay an Article Processing Charge (APC). The final version of the published article is then free to read for everyone.
Authors may need to take specific actions to achieve compliance with funder and institutional open access mandates. If your research is supported by a funder that requires immediate open access (e.g. according to Plan S principles) then you should select the gold OA route, and we will direct you to the compliant route where possible. For authors selecting the subscription publication route, the journal's standard licensing terms will need to be accepted, including self-archiving policies. Those licensing terms will supersede any other terms that the author or any third party may assert apply to any version of the manuscript.
Benefits of open access
Publishing open access offers a number of benefits, including greater reach and readership for your work:
1.6x more citations of OA articles than non-OA articles across all subjects
4x more downloads of OA articles than non-OA articles
2.5x more Altmetric attention. OA articles attracted 1.9x more news mentions and 1.2x more policy mentions
Find out more about benefits of open access.
Fees and Funding
Article-processing charges (APC)
Authors who choose to publish open access in Clinical Drug Investigation are required to pay an article-processing charge.
The APC for all published articles is as follows, subject to VAT or local taxes where applicable:
Visit our open access support portal for further information. Authors can also choose to publish under the traditional publishing model (no APC charges apply); both options will be offered after the paper has been accepted.
Open access funding
Visit Springer Nature’s open access funding & support services for information about research funders and institutions that provide funding for APCs.
Springer Nature offers agreements that enable institutions to cover open access publishing costs. Learn more about our open access agreements to check your eligibility and discover whether this journal is included.
Creative Commons licences
Open access articles in Springer Nature journals are published under Creative Commons licences. These provide an industry-standard framework to support easy re-use of open access material. Under Creative Commons licences, authors retain copyright of their articles.
Clinical Drug Investigation offers the Creative Commons Attribution Non-Commercial 4.0 International licence (CC BY-NC) as its default licence. This licence allows readers to copy and redistribute the material in any medium or format, and to alter, transform, or build upon the material, but not for commercial use.
In instances where authors are not allowed to retain copyright to their own article (where the author is a US Government employee for example), authors should contact the Open Research Support team (ORSupport@springernature.com) before submitting their article so we can advise as to whether their non-standard copyright request can be accommodated.
Authors are advised to check their funder's requirements before selecting open access, to ensure compliance. Learn more about funder compliance.
For authorsSubmit manuscript
Working on a manuscript?
Avoid the most common mistakes and prepare your manuscript for journal editors.Learn more